FDA clears MabSpace's PD-L1 mAb for first-in-human trial

MabSpace Biosciences Co. Ltd. (Suzhou, China) said FDA approved an IND to begin a Phase I trial of MSB2311 to treat advanced or metastatic solid tumors. MSB2311, a humanized IgG1 mAb targeting PD-L1, will be MabSpace's first compound to enter the clinic.

The trial will have an open-label, dose-escalation and dose-expansion design and plans to enroll about 40 patients. The primary endpoint is safety, and the secondary endpoint is pharmacokinetics...